Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis

NCT01359813 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

193

Enrollment

OTHER

Sponsor class

Stopped decision of independent monitoring committee:Risk of death at 3 months higher in Albumin group than in control group, without reaching significance level.

Conditions

Cirrhosis
Sepsis
Renal Failure

Interventions

DRUG: Human Albumin

Sponsor

Centre Hospitalier Universitaire de Besancon

Collaborators

[object Object]